Navigation Links
Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
Date:10/11/2010

SAN DIEGO, Oct. 11 /PRNewswire/ -- Essentialis, Inc. announced today that the United States Patent & Trademark Office (USPTO) has issued U.S. Patent No. 7,799,777 entitled Salts of potassium ATP channel openers and uses thereof. The patent claims a novel composition of a polymorph of diazoxide choline, the active ingredient in the Essentialis lead product, DCCR.  Essentialis has successfully completed phase 2b clinical trials with DCCR, showing a highly significant triglyceride reduction in dyslipidemic patients.

"The granting of this patent further secures our intellectual property position on the active component in DCCR", said Aaron Berg, Chief Commercial Officer of Essentialis.  "This patent combined with our previously issued patents provide Essentialis with broad patent protection on our drug active, pharmaceutical formulations, methods of use and methods of manufacturing DCCR which currently extends to 2028."  

DCCR is the first product in a new class of dyslipidemia treatment, with a mechanism of action distinct from other dyslipidemia treatments.  In Phase 2b clinical studies, DCCR has demonstrated the potential to lower triglycerides (30-50%), non-HDL cholesterol and Apo B (10-15%) while raising HDL-cholesterol (5-10%). DCCR reduces the production of triglyceride rich lipoprotein particles before they can accumulate and contribute to the progression of pancreatitis and cardiovascular disease. Currently available dsylipidemia treatments (such as fibrates and omega 3 fatty acid products) work primarily by increasing clearance of triglycerides from the blood stream.

"DCCR's unique mechanism of action will allow for additive efficacy with statins and other lipid-lowering agents to better achieve desired lipid targets," said Neil Cowen, Ph.D., Co-founder and Chief Scientific Officer for Essentialis.  "Once a patient maximizes their benefit from one agent, additional therapeutic benefit may be achieved with DCCR, helping them reach lipid goals."

Patients taking DCCR experience mostly mild to moderate, transient adverse events, the most frequent of which included increases in fasting plasma glucose that are similar to or less than those seen with niacin, another lipid-lowering drug, peripheral edema similar to what is seen with calcium channel blocking antihypertensives, and headaches.

About Very High Triglycerides

Hypertriglyceridemia, a disease where patients have high blood levels of triglycerides, is associated with increased risk of coronary heart disease even after LDL-cholesterol targets have been achieved. Very high triglycerides are associated with an increased risk of developing pancreatitis. There are approximately 4 million patients in the US with very high triglycerides. The leading products for treating very high triglycerides, Lovaza® and fenofibrate, while effective, also cause significant elevations in LDL-cholesterol.

About Essentialis

Essentialis is a pharmaceutical company based in San Diego, CA focused on the development of breakthrough medicines for the treatment of cardiovascular and metabolic diseases. The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases.


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis to Submit SPA for Hypertriglyceridemia
2. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
3. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
4. American Medical Systems Strengthens Global Expansion With GreenLight HPS® Acquisitions in Australia
5. PAREXEL Opens New Office in Japan and Further Strengthens Leading Presence in Asia/Pacific Region
6. Webmedx Strengthens Quality Program and Improves Patient Safety in Compliance with New Industry Standards for Clinical Documentation
7. Pepscan Therapeutics Strengthens Management Team
8. Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo
9. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
10. Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering
11. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):